{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:09:45Z","timestamp":1772892585918,"version":"3.50.1"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.leukres.2024.107544","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T16:31:15Z","timestamp":1719333075000},"page":"107544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Multiple myeloma and infections in the era of novel treatment modalities"],"prefix":"10.1016","volume":"143","author":[{"given":"Mobil","family":"Akhmedov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pervin","family":"Zeynalova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Fedenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"36","key":"10.1016\/j.leukres.2024.107544_bib1","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party","volume":"23","author":"Augustson","year":"2005","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2024.107544_bib2","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/s41375-018-0133-x","article-title":"A predictive model for risk of early grade\u2009\u2265\u20093 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial","volume":"32","author":"Dumontet","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107544_bib3","article-title":"Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients","author":"Mai","year":"2023","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.leukres.2024.107544_bib4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.leukres.2024.107544_bib5","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","article-title":"Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022","volume":"57","author":"Snowden","year":"2022","journal-title":"Bone Marrow Transpl."},{"issue":"5","key":"10.1016\/j.leukres.2024.107544_bib6","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2141.2007.06705.x","article-title":"Immunodeficiency and immunotherapy in multiple myeloma","volume":"138","author":"Pratt","year":"2007","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.leukres.2024.107544_bib7","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3324\/haematol.2011.054015","article-title":"Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study","volume":"97","author":"Kristinsson","year":"2012","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.leukres.2024.107544_bib8","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1182\/blood-2007-10-121285","article-title":"Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders","volume":"111","author":"Brown","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2024.107544_bib9","doi-asserted-by":"crossref","first-page":"294","DOI":"10.7326\/0003-4819-129-4-199808150-00005","article-title":"Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection","volume":"129","author":"Andreone","year":"1998","journal-title":"Ann. Intern Med"},{"issue":"6","key":"10.1016\/j.leukres.2024.107544_bib10","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/j.1572-0241.2002.05668.x","article-title":"Role of Helicobacter pylori infection in the incidence and clinical course of monoclonal gammopathy of undetermined significance","volume":"97","author":"Malik","year":"2002","journal-title":"Am. J. Gastroenterol."},{"issue":"4 Suppl 3","key":"10.1016\/j.leukres.2024.107544_bib11","article-title":"Prevalence of monoclonal gammopathy in HIV patients in 2014","volume":"17","author":"Genet","year":"2014","journal-title":"J. Int AIDS Soc."},{"key":"10.1016\/j.leukres.2024.107544_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.876271","article-title":"Autoimmunity, infections, and the risk of monoclonal gammopathy of undetermined significance","volume":"13","author":"Sigurbergsd\u00f3ttir","year":"2022","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.leukres.2024.107544_bib13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.leukres.2024.107544_bib14","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/bjh.13532","article-title":"Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy","volume":"171","author":"Teh","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.leukres.2024.107544_bib15","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/ejh.13190","article-title":"Risk factors for infections in newly diagnosed Multiple Myeloma patients: a Danish retrospective nationwide cohort study","volume":"102","author":"S\u00f8rrig","year":"2019","journal-title":"Eur. J. Haematol."},{"issue":"6","key":"10.1016\/j.leukres.2024.107544_bib16","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/s41375-018-0133-x","article-title":"A predictive model for risk of early grade\u2009\u2265\u20093 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial","volume":"32","author":"Dumontet","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.leukres.2024.107544_bib17","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41408-022-00652-2","article-title":"A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma","volume":"12","author":"Encinas","year":"2022","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.leukres.2024.107544_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-021-08451-x","article-title":"Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019","volume":"21","author":"Balmaceda","year":"2021","journal-title":"BMC Cancer"},{"issue":"16","key":"10.1016\/j.leukres.2024.107544_bib19","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.2019000241","article-title":"Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma","volume":"134","author":"Rosi\u00f1ol","year":"2019","journal-title":"Blood"},{"issue":"10068","key":"10.1016\/j.leukres.2024.107544_bib20","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet Lond. Engl."},{"issue":"33","key":"10.1016\/j.leukres.2024.107544_bib21","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2014.58.7618","article-title":"Community-based phase iiib trial of three UPFRONT bortezomib-based myeloma regimens","volume":"33","author":"Niesvizky","year":"2015","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.leukres.2024.107544_bib22","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med"},{"issue":"8","key":"10.1016\/j.leukres.2024.107544_bib23","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2024.107544_bib24","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.autrev.2010.11.009","article-title":"The kaleidoscope of glucorticoid effects on immune system","volume":"10","author":"Zen","year":"2011","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.leukres.2024.107544_bib25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2024.107544_bib26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3390\/cancers12020265","article-title":"Proteasome inhibitors for the treatment of multiple myeloma","volume":"12","author":"Ito","year":"2020","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.leukres.2024.107544_bib27","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1111\/bjh.16735","article-title":"Infection risk with carfilzomib in multiple myeloma: a systematic review and meta-analysis of randomised controlled trials","volume":"190","author":"Wongsaengsak","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.leukres.2024.107544_bib28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107544_bib29","first-page":"21","article-title":"Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis","volume":"67","author":"Teh","year":"2016","journal-title":"Eur. J. Cancer Oxf. Engl. 1990"},{"issue":"5","key":"10.1016\/j.leukres.2024.107544_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0303537","article-title":"Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Yang","year":"2013","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.leukres.2024.107544_bib31","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1600-0609.2012.01814.x","article-title":"Infection complications in an unselected cohort of patients with multiple myeloma treated with lenalidomide combinations","volume":"89","author":"Caravita","year":"2012","journal-title":"Eur. J. Haematol."},{"issue":"Supplement_1","key":"10.1016\/j.leukres.2024.107544_bib32","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2019-123169","article-title":"Updated meta-analysis of randomized controlled trials to evaluate the incidence of infection and pneumonia in patients with multiple myeloma treated with daratumumab","volume":"134","author":"Htut","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2024.107544_bib33","doi-asserted-by":"crossref","DOI":"10.1177\/03000605211038135","article-title":"Efficacy and safety of daratumumab in the treatment of multiple myeloma: a systematic review and meta-analysis","volume":"49","author":"Wang","year":"2021","journal-title":"J. Int Med Res"},{"key":"10.1016\/j.leukres.2024.107544_bib34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2021.05.038","article-title":"Risk for infections with selinexor in patients with relapsed\/refractory multiple myeloma: a systematic review of clinical trials","volume":"154","author":"Abid","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.leukres.2024.107544_bib35","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14172","article-title":"Infectious complications in allogeneic hematopoietic cell transplant recipients: Review of transplant-related risk factors and current state of prophylaxis","volume":"35","author":"Akhmedov","year":"2021","journal-title":"Clin. Transpl."},{"issue":"9","key":"10.1016\/j.leukres.2024.107544_bib36","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/sj.bmt.1703920","article-title":"Surveillance of nosocomial infections in adult recipients of allogeneic and autologous bone marrow and peripheral blood stem-cell transplantation","volume":"31","author":"Dettenkofer","year":"2003","journal-title":"Bone Marrow Transpl."},{"issue":"4","key":"10.1016\/j.leukres.2024.107544_bib37","article-title":"Early infectious complications after autologous hematopoietic cell transplantation for multiple myeloma","volume":"21","author":"Rahman","year":"2019","journal-title":"Transpl. Infect. Dis. J. Transpl. Soc."},{"issue":"9","key":"10.1016\/j.leukres.2024.107544_bib38","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/bmt.2010.286","article-title":"Impact of bloodstream infections on outcome and the influence of prophylactic oral antibiotic regimens in allogeneic hematopoietic SCT recipients","volume":"46","author":"Liu","year":"2011","journal-title":"Bone Marrow Transpl."},{"issue":"1","key":"10.1016\/j.leukres.2024.107544_bib39","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.bbmt.2012.08.016","article-title":"Bacteremia in blood or marrow transplantation patients: clinical risk factors for infection and emerging antibiotic resistance","volume":"19","author":"Bock","year":"2013","journal-title":"Biol. Blood Marrow Transpl. J. Am. Soc. Blood Marrow Transpl."},{"key":"10.1016\/j.leukres.2024.107544_bib40","doi-asserted-by":"crossref","unstructured":"Akhmedov M., Klyasova G., Kuzmina L., Vasilyeva V., Drokov M., Parovichnikova E. Incidence, etiology, risk factors and outcomes of pre-engraftment bloodstream infections after first and second allogeneic hematopoietic cell transplantation. Transpl Infect Dis. n\/a(n\/a). doi:10.1111\/tid.13842.","DOI":"10.1111\/tid.13842"},{"issue":"6","key":"10.1016\/j.leukres.2024.107544_bib41","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/bmt.2014.37","article-title":"Etiology, clinical features and outcomes of pre-engraftment and post-engraftment bloodstream infection in hematopoietic SCT recipients","volume":"49","author":"Gudiol","year":"2014","journal-title":"Bone Marrow Transpl."},{"issue":"2","key":"10.1016\/j.leukres.2024.107544_bib42","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3947\/ic.2022.0146","article-title":"Post-engraftment Bloodstream Infections After Allogeneic Hematopoietic Cell Transplantation: Risk Factors and Association with Mortality","volume":"55","author":"Akhmedov","year":"2023","journal-title":"Infect. Chemother."},{"issue":"4","key":"10.1016\/j.leukres.2024.107544_bib43","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jinf.2013.12.006","article-title":"Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients","volume":"68","author":"Mikulska","year":"2014","journal-title":"J. Infect."},{"issue":"12","key":"10.1016\/j.leukres.2024.107544_bib44","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1080\/10428190701694178","article-title":"Characteristics of and risk factors for pneumonia in patients with hematological malignancies developing fever after autologous blood stem cell transplantation","volume":"48","author":"Puig","year":"2007","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.leukres.2024.107544_bib45","doi-asserted-by":"crossref","first-page":"E629","DOI":"10.1111\/j.1399-0012.2011.01495.x","article-title":"Pneumonia in allogeneic stem cell transplantation recipients: a multicenter prospective study","volume":"25","author":"Aguilar-Guisado","year":"2011","journal-title":"Clin. Transpl."},{"issue":"10","key":"10.1016\/j.leukres.2024.107544_bib46","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1586\/eri.10.95","article-title":"Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients","volume":"8","author":"Chopra","year":"2010","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.leukres.2024.107544_bib47","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1469-0691.2006.01580.x","article-title":"Emergence of Clostridium difficile-associated disease in North America and Europe","volume":"12","author":"Kuijper","year":"2006","journal-title":"Clin. Microbiol Infect."},{"key":"10.1016\/j.leukres.2024.107544_bib48","article-title":"Clostridium Difficile Colonization and Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation","volume":"6","author":"Bruminhent","year":"2014","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"8","key":"10.1016\/j.leukres.2024.107544_bib49","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s00277-020-04149-5","article-title":"Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma","volume":"99","author":"Kaiser","year":"2020","journal-title":"Ann. Hematol."},{"issue":"15_suppl","key":"10.1016\/j.leukres.2024.107544_bib50","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.8016","article-title":"Maintenance therapy (MT) with 25 versus 5 mg lenalidomide (Len) after prolonged Len consolidation therapy (CT) in newly-diagnosed, transplant-eligible patients (pts) with multiple myeloma (MM)","volume":"36","author":"Fenk","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2024.107544_bib51","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20170304","article-title":"Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysis","volume":"37","author":"Sun","year":"2017","journal-title":"Biosci. Rep."},{"issue":"1","key":"10.1016\/j.leukres.2024.107544_bib52","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/ejh.13709","article-title":"Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group","volume":"108","author":"Gregersen","year":"2022","journal-title":"Eur. J. Haematol."},{"issue":"10","key":"10.1016\/j.leukres.2024.107544_bib53","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.leukres.2024.107544_bib54","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.leukres.2024.107544_bib55","article-title":"Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies","volume":"25","author":"Kampouri","year":"2023","journal-title":"Transpl. Infect. Dis. J. Transpl. Soc."},{"issue":"11","key":"10.1016\/j.leukres.2024.107544_bib56","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"10.1016\/j.leukres.2024.107544_bib57","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N. Engl. J. Med"},{"issue":"7","key":"10.1016\/j.leukres.2024.107544_bib58","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy","volume":"6","author":"Kambhampati","year":"2022","journal-title":"Blood Adv."},{"issue":"24","key":"10.1016\/j.leukres.2024.107544_bib59","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1182\/bloodadvances.2022008320","article-title":"Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma","volume":"6","author":"Logue","year":"2022","journal-title":"Blood Adv."},{"issue":"10","key":"10.1016\/j.leukres.2024.107544_bib60","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41408-021-00563-8","article-title":"Viral infection\/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy","volume":"11","author":"Wang","year":"2021","journal-title":"Blood Cancer J."},{"issue":"6","key":"10.1016\/j.leukres.2024.107544_bib61","doi-asserted-by":"crossref","first-page":"304.e1","DOI":"10.1016\/j.jtct.2022.03.005","article-title":"Pathogen-Specific Humoral Immunity and Infections in B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Recipients with Multiple Myeloma","volume":"28","author":"Josyula","year":"2022","journal-title":"Transpl. Cell Ther."},{"issue":"6","key":"10.1016\/j.leukres.2024.107544_bib62","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med"},{"issue":"24","key":"10.1016\/j.leukres.2024.107544_bib63","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell\u2013Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med"},{"issue":"9","key":"10.1016\/j.leukres.2024.107544_bib64","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med"},{"issue":"13","key":"10.1016\/j.leukres.2024.107544_bib65","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv."},{"issue":"19","key":"10.1016\/j.leukres.2024.107544_bib66","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.leukres.2024.107544_bib67","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2024.107544_bib68","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Drayson","year":"2019","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2024.107544_bib69","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol."},{"issue":"2","key":"10.1016\/j.leukres.2024.107544_bib70","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/jcpt.13298","article-title":"Association of prior fluoroquinolone treatment with survival outcomes of immune checkpoint inhibitors in Asia","volume":"46","author":"Lu","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"issue":"4","key":"10.1016\/j.leukres.2024.107544_bib71","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41591-022-01702-9","article-title":"Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy","volume":"28","author":"Smith","year":"2022","journal-title":"Nat. Med"},{"issue":"11","key":"10.1016\/j.leukres.2024.107544_bib72","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/cid\/ciy363","article-title":"Colonization With Levofloxacin-resistant Extended-spectrum \u03b2-Lactamase-producing Enterobacteriaceae and Risk of Bacteremia in Hematopoietic Stem Cell Transplant Recipients","volume":"67","author":"Satlin","year":"2018","journal-title":"Clin. Infect. Dis. Publ. Infect. Dis. Soc. Am."},{"issue":"7","key":"10.1016\/j.leukres.2024.107544_bib73","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/cid\/ciab404","article-title":"Colonization With Fluoroquinolone-Resistant Enterobacterales Decreases the Effectiveness of Fluoroquinolone Prophylaxis in Hematopoietic Cell Transplant Recipients","volume":"73","author":"Satlin","year":"2021","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.leukres.2024.107544_bib74","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jinf.2016.07.002","article-title":"Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies","volume":"73","author":"Satlin","year":"2016","journal-title":"J. Infect."},{"issue":"6","key":"10.1016\/j.leukres.2024.107544_bib75","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1080\/10428194.2023.2197532","article-title":"Impact of fluoroquinolone administration and gut mucosal colonization on the risk of pre-engraftment bloodstream infections after allogeneic hematopoietic cell transplantation","volume":"64","author":"Akhmedov","year":"2023","journal-title":"Leuk. Lymphoma"},{"issue":"2","key":"10.1016\/j.leukres.2024.107544_bib76","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/bmt.2014.231","article-title":"Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy","volume":"50","author":"Girmenia","year":"2015","journal-title":"Bone Marrow Transpl."},{"issue":"12","key":"10.1016\/j.leukres.2024.107544_bib77","first-page":"3221","article-title":"European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia","volume":"73","author":"Maertens","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.leukres.2024.107544_bib78","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J."},{"issue":"12S","key":"10.1016\/j.leukres.2024.107544_bib79","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.bulcan.2021.11.001","article-title":"[Prevention and management of infections in patients undergoing CAR T-cell therapy: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]","volume":"108","author":"Paul","year":"2021","journal-title":"Bull. Cancer (Paris)"},{"issue":"11","key":"10.1016\/j.leukres.2024.107544_bib80","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1600-0463.2012.02922.x","article-title":"Serologic response to a 23-valent pneumococcal vaccine administered prior to autologous stem cell transplantation in patients with multiple myeloma","volume":"120","author":"Hinge","year":"2012","journal-title":"APMIS Acta Pathol. Microbiol Immunol. Scand."},{"key":"10.1016\/j.leukres.2024.107544_bib81","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.trivac.2013.09.001","article-title":"Pneumococcal vaccine responses in elderly patients with multiple myeloma, Waldenstrom\u2019s macroglobulinemia, and monoclonal gammopathy of undetermined significance","volume":"2","author":"Karlsson","year":"2013","journal-title":"Trials Vaccin."},{"issue":"6","key":"10.1016\/j.leukres.2024.107544_bib82","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1016\/S1473-3099(18)30601-7","article-title":"Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Mikulska","year":"2019","journal-title":"Lancet Infect. Dis."},{"issue":"6","key":"10.1016\/j.leukres.2024.107544_bib83","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/s41375-023-01920-1","article-title":"Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)","volume":"37","author":"Terpos","year":"2023","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.leukres.2024.107544_bib84","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S1473-3099(18)30600-5","article-title":"Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Cordonnier","year":"2019","journal-title":"Lancet Infect. Dis."},{"issue":"Suppl 1","key":"10.1016\/j.leukres.2024.107544_bib85","first-page":"21","article-title":"The use of intravenous immune globulin in multiple myeloma","volume":"97","author":"Chapel","year":"1994","journal-title":"Clin. Exp. Immunol."},{"issue":"12","key":"10.1016\/j.leukres.2024.107544_bib86","doi-asserted-by":"crossref","first-page":"831.e1","DOI":"10.1016\/j.jtct.2022.09.012","article-title":"A Prospective, Randomized Trial Examining the Use of G-CSF Versus No G-CSF in Patients Post-Autologous Transplantation","volume":"28","author":"Grosso","year":"2022","journal-title":"Transpl. Cell Ther."},{"issue":"4","key":"10.1016\/j.leukres.2024.107544_bib87","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N. Engl. J. Med"},{"issue":"25","key":"10.1016\/j.leukres.2024.107544_bib88","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"10192","key":"10.1016\/j.leukres.2024.107544_bib89","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.leukres.2024.107544_bib90","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol."},{"issue":"Supplement 1","key":"10.1016\/j.leukres.2024.107544_bib91","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2023-177546","article-title":"Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients","volume":"142","author":"Gay","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2024.107544_bib92","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma","volume":"42","author":"Leypoldt","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2024.107544_bib93","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/S2352-3026(23)00366-6","article-title":"Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial","volume":"11","author":"Mai","year":"2024","journal-title":"Lancet Haematol."},{"issue":"16_suppl","key":"10.1016\/j.leukres.2024.107544_bib94","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.8000","article-title":"Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study","volume":"41","author":"Knop","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2024.107544_bib95","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jamaoncol.2021.0611","article-title":"Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial","volume":"7","author":"Landgren","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.leukres.2024.107544_bib96","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1182\/blood-2023-173126","article-title":"Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study","volume":"142","author":"Askeland","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2024.107544_bib97","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1016\/S2352-3026(22)00103-X","article-title":"Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial","volume":"9","author":"Dimopoulos","year":"2022","journal-title":"Lancet Haematol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624001103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624001103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T17:39:27Z","timestamp":1732297167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212624001103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":97,"alternative-id":["S0145212624001103"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107544","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple myeloma and infections in the era of novel treatment modalities","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107544","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107544"}}